SEC Comment Letter for Summit Therapeutics Inc. (SMMT) (CIK 0001599298) (SMMT) — Jun 14, 2019
Summit Therapeutics Inc. (SMMT) (CIK 0001599298)
Date: June 14, 2019 · CIK: 0001599298 · Accession: 0000000000-19-009889
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-232074
Letter
June 14, 2019 Glyn Edwards Chief Executive Officer Summit Therapeutics plc 136a Eastern Avenue Milton Park, Abingdon Oxfordshire OX14 4SB United Kingdom Re:Summit Therapeutics plc Registration Statement on Form F-3 Filed June 12, 2019 File No. 333-232074 Dear Mr. Edwards: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tonya K. Aldave at (202) 551-3601 with any questions. Sincerely, Division of Corporation Finance Office of Healthcare & Insurance cc: Brian Johnson, Esq.
Show Raw Text
June 14, 2019
Glyn Edwards
Chief Executive Officer
Summit Therapeutics plc
136a Eastern Avenue
Milton Park, Abingdon
Oxfordshire OX14 4SB
United Kingdom
Re:Summit Therapeutics plc
Registration Statement on Form F-3
Filed June 12, 2019
File No. 333-232074
Dear Mr. Edwards:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tonya K. Aldave at (202) 551-3601 with any questions.
Sincerely,
Division of Corporation Finance
Office of Healthcare & Insurance
cc: Brian Johnson, Esq.